Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Total Liabilities (2016 - 2025)

BioCorRx's Total Liabilities history spans 16 years, with the latest figure at $20.3 million for Q3 2025.

  • For Q3 2025, Total Liabilities rose 60.5% year-over-year to $20.3 million; the TTM value through Sep 2025 reached $20.3 million, up 60.5%, while the annual FY2024 figure was $12.7 million, 23.21% up from the prior year.
  • Total Liabilities for Q3 2025 was $20.3 million at BioCorRx, up from $19.7 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $20.3 million in Q3 2025 and bottomed at $6.1 million in Q2 2021.
  • The 5-year median for Total Liabilities is $9.5 million (2023), against an average of $10.9 million.
  • The largest annual shift saw Total Liabilities decreased 2.38% in 2021 before it surged 69.4% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $7.8 million in 2021, then rose by 15.25% to $9.0 million in 2022, then grew by 15.31% to $10.3 million in 2023, then rose by 23.21% to $12.7 million in 2024, then skyrocketed by 59.31% to $20.3 million in 2025.
  • Per Business Quant, the three most recent readings for BICX's Total Liabilities are $20.3 million (Q3 2025), $19.7 million (Q2 2025), and $18.6 million (Q1 2025).